Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity.

ABSTRACT:

Purpose

To report 2-year ocular and developmental outcomes for infants receiving low doses of intravitreal bevacizumab for type 1 retinopathy of prematurity (ROP).

Methods

A total of 120 premature infants (mean birthweight, 687 g; mean gestational age, 24.8 weeks) with type 1 ROP were enrolled in a multicenter, phase 1 dose de-escalation study. One eye per infant received 0.25 mg, 0.125 mg, 0.063 mg, 0.031 mg, 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg of intravitreal bevacizumab; fellow eyes when treated received one dosage level higher. At 2 years, 70 of 120 children (58%) underwent ocular examinations; 51 (43%) were assessed using the Bayley Scale of Infant and Toddler Development.

Results

Correlation coefficients for the association of total dosage of bevacizumab w

SUBMITTER: Wallace DK 

PROVIDER: S-EPMC10729831 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature